Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q2 2023 call → NOThe question asks whether management conveys that the company today is running on a different basis than its reported results and reputation were built on — that is, whether management describes the company as having crossed into being a different kind of business, while making clear that this change is not yet reflected in the reported numbers or outside perception. Let me analyze the transcript carefully. Key elements from the call: 1. Amir London's opening remarks: "I'm pleased to report the strong start to 2023 continued in the second quarter, both financially and operationally. And we are well positioned to achieve our 2023 full year guidance..." 2. He discusses multiple growth drivers: "a significant increase in KEDRAB sales and Kedrion for further distribution in the U.S., the portfolio of four FDA-approved hemoglobins acquired in late 2021: CYTOGAM, HEPAGAMB, VARIZIG and WINRHO and our Israeli distribution business." 3. He mentions the FIMI investment: "we entered into a securities purchase agreement with FIMI... FIMI will purchase an additional $16 million of our ordinary shares in a private placement... Upon the closing of the transaction, FIMI is expected to beneficially own approximately 38% of Kamada's outstanding ordering shares and it will become the controlling shareholder..." 4. He discusses KEDRAB: "we were pleased to announce last month that Kedrion has exercised its option to extend our distribution agreement for KEDRAB in the U.S. through March 2026." 5. He discusses the U.S. team: "our U.S. team established during 2022 continues to achieve good progress in promoting our specialty immunoglobulin portfolio..." 6. He discusses CYTOGAM manufacturing: "in May of this year, we announced FDA approval of our application to manufacture CYTOGAM at our Israeli facility after completing the technology transfer... I'm happy to report today that we recently obtained a similar approval from Health Canada, thereby successfully completing the tech transfer of this product." 7. He discusses Kamada Plasma: "We continue to be pleased with the progress we made at Kamada Plasma, our U.S. based plasma collection company. Our 2021 acquisition of the plasma collection center in Beaumont, Texas represented Kamada's entry into the U.S. plasma collection market and supported our strategic goal of becoming a fully integrated specialty plasma product company." 8.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...